Alphabet's AI Drug Discovery Arm Isomorphic Labs Secures $600M Funding
Summary
Alphabet's AI drug discovery subsidiary Isomorphic Labs secures $600 million funding from Thrive Capital to accelerate development of its AI-powered drug design platform and advance its drug candidates into clinical trials, leveraging technology like DeepMind's AlphaFold.
Key Points
- Alphabet's AI drug discovery platform Isomorphic Labs raises $600M from Thrive Capital.
- The funding will accelerate development of Isomorphic's AI drug design engine and support bringing its discovered drugs to clinical trials.
- Isomorphic Labs was founded by DeepMind co-founder Demis Hassabis, leveraging DeepMind's AI drug discovery software like AlphaFold.